Phio Pharmaceuticals Announces Participation in Third Annual DealFlow Discovery Conference
King of Prussia, Pennsylvania--(Newsfile Corp. - January 26, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today announced that it will participate in the DealFlow Discovery Conference, taking place January 28-29, 2026 at the Borgata Hotel in Atlantic City, NJ. Robert Bitterman, CEO and Chairman of th
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-01-26 8:15 AM EST | Phio Pharmaceuticals Corp.
Optimi Health Completes First 2026 Production of MDMA and Psilocybin Capsules
Vancouver, British Columbia--(Newsfile Corp. - January 26, 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Health Canada-licensed manufacturer of pharmaceutical psychedelic drug products, today reported that it has completed a production cycle for its MDMA and psilocybin capsules intended for supply into Australia under the Authorised Prescriber Scheme. The completed batch consists of 1,000 MDMA capsules in a 60 mg dosage form and 1,000 n
Biotechnology, Pharmaceuticals, Health, Psychedelics
2026-01-26 7:00 AM EST | Optimi Health Corp.
Herbal Dispatch Approved for Listing on the OTCQB
Vancouver, British Columbia--(Newsfile Corp. - January 26, 2026) - Herbal Dispatch Inc. (CSE: HERB) (OTCQB: LUFFF) (FSE: HA9) ("Herbal Dispatch" or the "Company"), a leading cannabis e-commerce and distribution platform, is pleased to announce that effective today, the Company's common shares have commenced trading on the OTCQB® Venture Market ("OTCQB") under the ticker symbol "LUFFF". This listing enhances accessibility for U.S. bas
Pharmaceuticals, Cannabis, Cannabis Dispensary
2026-01-26 3:01 AM EST | Herbal Dispatch Inc.
TempraMed Launches New Product "VIVI Med(TM)," Unlocking New Growth Opportunities in High-Value Biologics and Injectable Medications
Highlights Uses same fully patented, thermal-protection technology across product portfolio with four products in market that keep room temperature medications at optimal temperature Designed for medications beyond standard insulin pens, including vials, biologics, GLP-1 therapies, alternative epinephrine auto-injectors, and temperature- and light-sensitive glucose test strips Expanded portfolio to pursue larger
Technology, Biotechnology, Pharmaceuticals, Health
2026-01-23 4:05 PM EST | TempraMed Technologies Ltd
Herbal Dispatch Announces 298kg Export Destined for German Market
Vancouver, British Columbia--(Newsfile Corp. - January 22, 2026) - Herbal Dispatch Inc. (CSE: HERB) (OTCID: LUFFF) (FSE: HA9) ("Herbal Dispatch" or the "Company") a leading cannabis e-commerce and distribution platform, is pleased to announce that it has completed a 298kg export of medical cannabis that is destined for the German medical cannabis market. The export was exported through Portugal to a new export relationship that is expected to provide strong revenue oppor
Pharmaceuticals, Cannabis, Cannabis Dispensary
2026-01-22 3:36 AM EST | Herbal Dispatch Inc.
CBIH Evaluates a Potential Reg A Offering of Approximately $1,000,000 to Enable Commercial Launch, Statewide Educational Expansion, and Protection of Its Patent Portfolio
Houston, Texas--(Newsfile Corp. - January 21, 2026) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public company trading on the OTC Markets under the ticker symbol CBIH, announced today that it is in the evaluation stage of a potential financing transaction under Regulation A (Reg A), in an estimated amount in the order of $1,000,000, subject to change, internal review, and applicable market and compliance conditions. CBIH clarifies that this communication reflects
Biotechnology, Pharmaceuticals, Cannabis, Health
2026-01-21 7:00 AM EST | Cannabis Bioscience International Holdings
Defence Therapeutics Sharpens Strategic Focus on Precision Drug Delivery to Unlock the Full Potential of Cancer Biologics
Montreal, Quebec--(Newsfile Corp. - January 21, 2026) - Defence Therapeutics Inc., (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a publicly traded biotechnology company, today announced an evolution of its corporate positioning to reflect its focus as a precision intracellular drug-delivery company advancing its proprietary Accum® platform through both internal development programs and strategic partnerships. Designed to unlock the full potential of comple
Biotechnology, Pharmaceuticals, Health
2026-01-21 3:15 AM EST | Defence Therapeutics Inc.
Phio Pharmaceuticals Announces Key Tumor Response Data from all Cohorts in Intratumoral PH-762 Dose Escalation Cutaneous Carcinoma Trial
King of Prussia, Pennsylvania--(Newsfile Corp. - January 20, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio an
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-01-20 9:30 AM EST | Phio Pharmaceuticals Corp.
Telescope Innovations Plans Expansion of DirectInject-LC(TM) Technology Ecosystem to Fuel the Physical AI Revolution
Vancouver, British Columbia--(Newsfile Corp. - January 20, 2026) - Telescope Innovations Corp., (CSE: TELI) (OTCQB: TELIF) (FSE: J4U) ("Telescope" or the "Company"), is a leader in Physical AI, Self-Driving Laboratories, and enabling technology supporting autonomous laboratory infrastructure. The Company is pleased to provide a look at its planned 2026 technology development pipeline, which aligns with its Self-Driving Lab (SDL) architecture for autonomous chemistry R&D. Buildin
Technology, Chemical, Pharmaceuticals, Psychedelics
2026-01-20 8:00 AM EST | Telescope Innovations Corp.
BioVaxys Reports Positive Clinical Study Results from Phase 1B/2 PESCO Trial of MVP-S with Pembrolizumab (Keytruda (TM)) and Low-Dose Cyclophosphamide for Patients with Recurrent Epithelial Ovarian Cancer (EOC)
Vancouver, British Columbia--(Newsfile Corp. - January 20, 2026) - BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB0) (OTCQB: BVAXF) ("BioVaxys" or the "Company"), a clinical stage biotechnology company focused on developing advanced treatments in oncology, in
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-01-20 8:00 AM EST | BioVaxys Technology Corp.
NuGen Medical Devices Provides 2025 Year End Update on R&D and Strategic Progress
Toronto, Ontario--(Newsfile Corp. - January 16, 2026) - NuGen Medical Devices Inc. (TSXV: NGMD) ("NuGen" or the "Company"), a leader in needle-free subcutaneous drug-delivery technology, is providing a summary of key developments achieved during 2025 across its Research and Development programs, technical capabilities, clinical initiatives, and global commercial activities. 2025 Operational Highlights Research & Development Demonstrate
Healthcare and Hospitals, Pharmaceuticals, Health
2026-01-16 5:30 PM EST | NuGen Medical Devices Inc.
Hemostemix Receives FDA Support for Its Basket Protocol Approach
Calgary, Alberta--(Newsfile Corp. - January 16, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous stem cell company treating those who suffer in pain from peripheral arterial disease, chronic limb threatening ischemia, angina, ischemic cardiomyopathy, dilated cardiomyopathy, and vascular dementia, in Florida, Canada, The Bahamas, announces the successful completion of its pre-Investigational New Drug (pre-IND) meeting with the U.S. Food and Drug Administra
Biotechnology, Pharmaceuticals, Health
2026-01-16 12:26 PM EST | Hemostemix Inc.
Optimi Health Announces Equity Incentive Grants and Corporate Update
Vancouver, British Columbia--(Newsfile Corp. - January 16, 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Canadian GMP-compliant manufacturer of MDMA and psilocybin, today announced a series of equity compensation and marketing initiatives designed to support its growth strategy and enhance market awareness. Equity Incentive Grants Optimi announces that, pursuant to its equity incentive plan and subject
Biotechnology, Pharmaceuticals, Health, Psychedelics
2026-01-16 7:00 AM EST | Optimi Health Corp.
Phio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor Conference January 21-22, 2026
King of Prussia, Pennsylvania--(Newsfile Corp. - January 15, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will present an update on the company's proprietary INTASYL siRNA technology and progress on the on-going clinical t
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-01-15 8:45 AM EST | Phio Pharmaceuticals Corp.
PharmaTher Expands PharmaPatch(TM) Platform into GLP-1 for Obesity, Leveraging Its Ketamine and Psychedelic Patch Programs
Toronto, Ontario--(Newsfile Corp. - January 14, 2026) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty pharmaceutical company focused on unlocking the therapeutic potential of ketamine, psychedelics, and GLP-1 drugs for neuropsychiatric and obesity disorders, today announced a new strategic initiative to expand its PharmaPatch™ microneedle patch platform into GLP-1 therapies for the potential treatment of obesity. PharmaT
Biotechnology, Pharmaceuticals
2026-01-14 8:00 AM EST | PharmaTher Holdings Ltd.
Optimi Health to Present at the Sidoti Micro-Cap Conference on January 21-22, 2026
Vancouver, British Columbia--(Newsfile Corp. - January 14, 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a leading producer of prescribed psychedelic treatments for mental health therapies, today announced that management has been invited to present at the Sidoti Micro-Cap Virtual Conference on January 21-22, 2026. Chief Executive Officer Dane Stevens is scheduled to host virtual one-on-one meetings with institutional invest
Biotechnology, Pharmaceuticals, Health, Psychedelics
2026-01-14 7:30 AM EST | Optimi Health Corp.
TempraMed Receives Positive Response on Payor Reimbursement Model Driving Significant Return on Investment for Medical Payor Coverage
Highlights ROI model validated for savings and metrics by Validation Institute, a leading authority in healthcare value and economic credibility Confirms that payors covering VIVI Cap™ can achieve meaningful cost savings and return on investment Supports TempraMed's planned payor pilot programs aimed at confirming savings and securing reimbursement coverage Establishe
Technology, Biotechnology, Pharmaceuticals, Health
2026-01-14 2:00 AM EST | TempraMed Technologies Ltd
Utah Approves AI Prescriptions Drugs. How AI Is Saving Time, Cutting Costs - and Why Molecule.ai's Drug Discovery Platform Matters More Than Ever
Gaithersburg, Maryland--(Newsfile Corp. - January 13, 2026) - Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) ("Shuttle Pharma" or the "Company"), applauds the state of Utah which has become the first state in the United States to allow artificial intelligence systems to authorize prescription refills without direct physician involvement — a regulatory first that signals how AI is beginning to reduce healthcare costs, eliminate delays, and expand access to care. The pilot pr
2026-01-13 4:00 PM EST | Shuttle Pharmaceuticals Holdings Inc.
Third Consecutive Year of Double Digit Growth - Herbal Dispatch Recaps Key Milestones for 2025
Vancouver, British Columbia--(Newsfile Corp. - January 13, 2026) - Herbal Dispatch Inc. (CSE: HERB) (OTC Pink: LUFFF) (FSE: HA9) ("Herbal Dispatch" or the "Company") a leading cannabis e-commerce and distribution platform, is pleased to recap its key milestones achieved in 2025. In 2025, the Company continued to advance its strategic and operational objectives. Through notable sales growth, the completion of an over-subscribed private placement, and the introduction
Pharmaceuticals, Cannabis, Cannabis Dispensary
2026-01-13 3:01 AM EST | Herbal Dispatch Inc.
TempraMed Closes C$2.5 Million Fully Subscribed Private Placement
Vancouver, British Columbia--(Newsfile Corp. - January 12, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to announce the fully subscribed closing of its previously announced non-brokered private placement (the "Offering"), issuing 3,322,153 units (each, a "Unit") at a price of $0.76 p
Technology, Biotechnology, Pharmaceuticals, Health
2026-01-12 5:30 PM EST | TempraMed Technologies Ltd